TrademarkDir
SYNTHESIS-TO-CLINIC
LIVE

Serial Number

79336901

Owner

Quotient Sciences Ltd

Attorney

Jonathan P. Soifer

Filing Date

Nov 5, 2021

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

SYNTHESIS-TO-CLINIC Trademark

Serial Number: 79336901 • Registration: 7445088

SYNTHESIS-TO-CLINIC is a trademark filed by Quotient Sciences Ltd on November 5, 2021. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Quotient Sciences Ltd (2 trademarks)

Trent House Mere Way,

Entity Type: 99

Trademark Details

Filing Date

November 5, 2021

Registration Date

July 16, 2024

Published for Opposition

April 30, 2024

Goods & Services

Research services relating to the pharmaceutical, biotechnology and nutraceutical industry

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jan 16, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 16, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 16, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 16, 2026 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 10, 2025 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Dec 21, 2024 FICS
FINAL DISPOSITION PROCESSED
Dec 21, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 17, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 16, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 16, 2024 R.PR
REGISTERED-PRINCIPAL REGISTER
Jul 16, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2024 PUBO
NOTIFICATION PROCESSED BY IB
Apr 29, 2024 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 10, 2024 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2024 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 10, 2024 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 28, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 27, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 27, 2024 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 16, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 30, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 30, 2023 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 28, 2023 GNFN
FINAL REFUSAL E-MAILED
Aug 28, 2023 GNFR
FINAL REFUSAL WRITTEN
Aug 28, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 13, 2023 TROA
ASSIGNED TO EXAMINER
Mar 1, 2023 DOCK
REFUSAL PROCESSED BY IB
Jan 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 13, 2022 RFCS
REFUSAL PROCESSED BY MPU
Dec 13, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 30, 2022 RFCR
NON-FINAL ACTION WRITTEN
Sep 29, 2022 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Sep 28, 2022 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 24, 2022 RFCR
NON-FINAL ACTION WRITTEN
Aug 23, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 17, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 8, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 31, 2022 REPR

Related Trademarks

More from this Owner

TRANSLATIONAL PHARMACEUTICS

TRANSLATIONAL PHARMACEUTICS

TRANSLATIONAL PHARMACEUTICS

TRANSLATIONAL PHARMACEUTICS

TRANSLATIONAL PHARMACEUTICS

TRANSLATIONAL PHARMACEUTICS